NCIt definition : A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the
inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune
checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab
binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding
with major histocompatibility complex (MHC) class II molecules expressed on tumor
cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated
tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the
immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively
regulates both proliferation and activation of T-cells. Its expression on TILs is
associated with tumor-mediated immune suppression.;
UNII : H1396W7D1H;
CAS number : 2231068-83-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2231068-83-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)